interleukins (IL) and macrophage activation syndrome Archives

Abstract Number: 3006 • ACR/ARHP Annual Meeting 2016
IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)
Claudia Bracaglia¹, Denise Pires Marafon², Ivan Caiello², Kathy de Graaf³, Florence Guilhot³, Walter Ferlin³, Sergio Davì⁴, Grant Schulert⁵, Angelo Ravelli⁴, Alexei Grom⁶, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland, ⁴Istituto Giannina Gaslini, Genoa, Italy, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Evidence in animals and humans points to a pivotal role of IFNγ in primary HLH. We have recently generated data in an animal model…
Abstract Number: 2424 • ACR/ARHP Annual Meeting 2015
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program
Alexei A. Grom¹, Hermine I. Brunner¹, Nicolino Ruperto², Alberto Martini², Daniel Lovell^1,3, Virginia Pascual⁴, Karine Lheritier⁵, Karolynn Leon⁶, Ken Abrams⁶ and Norman Ilowite⁷, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Baylor Institute for Immunology Research, Dallas, TX, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Macrophage activation syndrome (MAS), a potentially fatal complication of systemic juvenile idiopathic arthritis (SJIA), was reported as an adverse event in both canakinumab and…

Abstracts tagged "interleukins (IL) and macrophage activation syndrome"

IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)

Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program